Chang Gung Memorial Hospital - Recruiting 18 years to 70 years. - Phase IV; Different Extend Treatment Duration (6 Months vs 12 Months After Chemotherapy) to Prevent HBV Relapse With Tenofovir for Prophylaxis in Patients With Malignant Tumor Combined With HBV Carrier Receiving Chemotherapy.
Institut de Recherche pour le Developpement - Recruiting 18 years or older. - Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization..
University of North Carolina, Chapel Hill - Recruiting 18 years or older. - CIDRZ-1220 Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA).
Rockefeller University - Recruiting 18 years to 60 years. - Effects of Persistent Innate Immune Activation on Vaccine Efficacy Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers.
Centers for Disease Control and Prevention - Recruiting 20 years or older. - Maternal Tenofovir-containing Combination Drug Regimen During the Second and Third Trimesters of Pregnancy for Prevention of Mother-to-child Transmission of HIV and HBV in HIV-HBV Co-infected Mothers.
Hoffmann-La Roche - Recruiting 18 years to 65 years. - A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression.
Hopital Lariboisire - Recruiting 18 years or older. - Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL.
Gilead Sciences - Recruiting 18 years or older. - A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B.
Tenofovir alafenamide; Tenofovir DF; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF
Gilead Sciences - Recruiting 18 years or older. - A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B.
Tenofovir alafenamide; Tenofovir disoproxil fumarate; Placebo to match tenofovir alafenamide; Placebo to match tenofovir DF
University Health Network, Toronto - Recruiting 18 years to 90 years. - Apoptosis and Hepatitis B: The Role of Apoptosis in Patients Who Are HBeAg Negative, Have Normal ALT, and HBV DNA ò10,000 Copies/mL.